Bioprocessing - Upstream & Downstream

Gene and Eva consider the importance of good record keeping.

How will biopharmaceutical process development be affected by next-generation technologies?

Gene encounters some challenges with chromatographic performance.

Rick Morris shares lessons learned based on a career of polymers and building biopharma equipment.

Thanks to the emergence of intensified and connected processes, the path to continuous biopharma manufacturing is open.

mAbs are an important growth area for the biopharma industry – so we need more effective purification technologies.

Antibody drug conjugates have not yet lived up to their potential, but there is hope – if we turn to the right solutions and techniques.

The challenge of convincing senior staff to invest in continuous bioprocessing.

Gene and Eva discuss the importance of being cautious when choosing a new supplier.